NewAmsterdam Pharma (NAMS) Accounts Payables (2022 - 2025)
Historic Accounts Payables for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $10.1 million.
- NewAmsterdam Pharma's Accounts Payables fell 455.58% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 455.58%. This contributed to the annual value of $13.6 million for FY2024, which is 1958.87% down from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma's Accounts Payables is $10.1 million, which was down 455.58% from $9.5 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Accounts Payables registered a high of $22.7 million during Q2 2023, and its lowest value of $8.0 million during Q1 2025.
- In the last 4 years, NewAmsterdam Pharma's Accounts Payables had a median value of $10.4 million in 2024 and averaged $13.0 million.
- Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 5510.92% in 2024, then tumbled by 455.58% in 2025.
- Quarter analysis of 4 years shows NewAmsterdam Pharma's Accounts Payables stood at $18.9 million in 2022, then dropped by 10.35% to $16.9 million in 2023, then fell by 19.59% to $13.6 million in 2024, then dropped by 25.79% to $10.1 million in 2025.
- Its Accounts Payables was $10.1 million in Q3 2025, compared to $9.5 million in Q2 2025 and $8.0 million in Q1 2025.